Item 2.02. Results of Operations and Financial Condition.

On May 5, 2022, BeiGene, Ltd. (the "Company") announced its financial results for the three months ended March 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 8.01. Other Events.

In its press release dated May 5, 2022, the Company also provided an update on the first quarter of 2022 and recent business highlights and expected milestones for the remainder of 2022 and 2023. The information in the press release set forth under the headings "Recent Business Highlights", "Expected Milestones" and "Forward-Looking Statements" is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

On May 4, 2022, the Company issued a press release announcing that the China National Medical Products Administration granted conditional approval of BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. A copy of this press release is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.                                              Description
99.1                     Press release titled "BeiGene Reports First Quarter 2022 Financial Results"
                         issued by BeiGene, Ltd. on May 5, 2022

99.2                     Press release titled "BeiGene Announces the Approval in China of BLINCYTO
                         (Blinatumomab) for Injection for Pediatric Patients with Relapsed or
                         Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)" issued by
                         BeiGene, Ltd. on May 4, 2022

104                      The cover page from this Current Report on Form 8-K, formatted in Inline
                         XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses